Holen Sie sich die Stockscreener-App
27.37
4.67%
-1.34
Vorhandelsmarkt:
26.74
-0.63
-2.30%
Schlusskurs vom Vortag:
$28.71
Offen:
$28
24-Stunden-Volumen:
931.58K
Relative Volume:
1.04
Marktkapitalisierung:
$1.64B
Einnahmen:
$439.00K
Nettoeinkommen (Verlust:
$-105.64M
KGV:
-15.21
EPS:
-1.8
Netto-Cashflow:
$-60.70M
1W Leistung:
+0.07%
1M Leistung:
+14.04%
6M Leistung:
-16.76%
1J Leistung:
-49.68%
1-Tages-Spanne:
$27.00
$29.21
1-Wochen-Bereich:
$27.00
$31.59
52-Wochen-Spanne:
$21.73
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Vergleichen Sie JANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
27.37 | 1.73B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Eingeleitet | Stifel | Buy |
| 2025-09-10 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-11 | Eingeleitet | Raymond James | Outperform |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Is Restile Ceramics Limited Stock Discounted Enough After Recent DeclinesRSI Overbought/Oversold & Fast Profit Stock Ideas - earlytimes.in
Can Janux Therapeutics Inc. stock surprise with earnings upsideTrade Volume Summary & Weekly Top Gainers Alerts - newser.com
Why Janux Therapeutics Inc. stock remains undervaluedWeekly Gains Summary & High Conviction Trade Alerts - newser.com
Is Janux Therapeutics Inc. stock a safe buy before earningsWeekly Investment Recap & Weekly Breakout Stock Alerts - newser.com
Using fundamentals and technicals on Janux Therapeutics Inc.Quarterly Trade Report & Fast Moving Stock Watchlists - newser.com
What analysts say about Janux Therapeutics Inc stockTechnology Stock Trends & Turn Data into Profits With Our Strategies - earlytimes.in
AlphaQuest LLC Has $224,000 Stock Holdings in Janux Therapeutics, Inc. $JANX - MarketBeat
Is Janux Therapeutics Inc. stock attractive for income investorsJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - newser.com
Will Janux Therapeutics Inc. price bounce be sustainable2025 Top Decliners & Consistent Return Investment Signals - newser.com
Insider Selling: Janux Therapeutics (NASDAQ:JANX) Insider Sells 16,665 Shares of Stock - MarketBeat
Janux Therapeutics Inc expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Volume spikes in Janux Therapeutics Inc. stock – what they meanMarket Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Exit strategy if you’re trapped in Janux Therapeutics Inc.Quarterly Market Review & Precise Trade Entry Recommendations - newser.com
Insider Sell: Andrew Meyer Sells Shares of Janux Therapeutics In - GuruFocus
Janux therapeutics CBO Meyer sells $500k in shares By Investing.com - Investing.com Canada
Janux Therapeutics: The Rumor Mill Spins Up Again (NASDAQ:JANX) - Seeking Alpha
Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last? - Yahoo Finance
Janux Therapeutics (JANX) Projected to Post Earnings on Wednesday - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Shares Up 8.6%Should You Buy? - MarketBeat
Exclusive BAC Article: Janux Therapeutics; 2nd Half Of 2025 JANX007 mCRPC Results Along With JANX008 In Metastatic Solid Tumors And Catalysts (NASDAQ:JANX) - Seeking Alpha
Is Janux Therapeutics Inc. stock positioned for long term growthJuly 2025 Movers & AI Powered Trade Plan Recommendations - fcp.pa.gov.br
Janux Therapeutics stock gains amid renewed takeover speculation - Seeking Alpha
Can Janux Therapeutics' Upcoming Immunotherapy Updates Drive A Stock Rebound? - RTTNews
Janux Therapeutics Advances with Promising Study on JANX008 for Solid Tumor Treatment - TipRanks
Janux Therapeutics Advances Prostate Cancer Study with JANX007 - TipRanks
Published on: 2025-10-27 07:20:07 - newser.com
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):